Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

Written by Customer Service on April 1, 2021. Posted in Public Companies.

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 03/31/2021 54,936,687 Total gross of voting rights: 54,936,687 Total net* of voting rights: 54,876,099 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2021

Written by Customer Service on April 1, 2021. Posted in Public Companies.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2021 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext ParisCode ISIN : FR 0010417345 Date Nombre totald’actionscomposant le capital social Nombre totalde droits de vote 31/03/2021 54 936 687 Total brut des droits de vote : 54 936 687 Total net* des droits de vote : 54 876 099 *Total net = nombre total de droits de vote attachés au nombre total d’actions – actions privées de droits de vote Pièce jointe version PDF

天演药业公布2020年全年财务业绩及最新业务进展

Written by Customer Service on April 1, 2021. Posted in Earnings Releases And Operating Results.

– 成功完成首次公开募股，总集资额约1.61亿美元 –– 公布了抗CD137和两个抗CTLA-4产品的临床数据 –– 将五个早期发现项目推进至新药申请的临床前研究阶段 –– 与学术界及行业内的多个合作伙伴建立了商业合作关系 –– 进一步强化了管理团队 – 中国苏州和美国旧金山, April 02, 2021 (GLOBE NEWSWIRE) — 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司于3月31日公布了截至2020年12月31日的全年财务业绩及公司最新业务进展。 “2020年天演取得了长足的进步。我们与学术界及行业内的多个合作伙伴建立了商业合作关系，并成功完成首次公开募股，总集资额约1.61亿美元，” 天演药业联合创始人、首席执行官兼董事长罗培志博士表示，“资金的支持将进一步帮助公司最大化技术平台以及独特产品管线的价值，加快临床前和临床产品开发。2021年将是天演药业至关重要的一年，我们期待接下来的一系列重要里程碑事件。” 近期业务亮点及预期里程碑 ADG106：天演药业第一个新表位抗体（NEObody™）项目。 ADG106是一种全人源配体阻断激动型抗CD137 IgG4单克隆抗体（mAb）。目前正在对晚期实体肿瘤和/或非霍奇金淋巴瘤患者进行评估。2021的重点将是启动以生物标志物为驱动的II期全球临床试验、确定最佳联合疗法，并探索细分适应症以加快获批速度。 2021年预期里程碑： 2021年上半年在中国开展的ADG106-1008联合疗法的Ib期数据 2021年下半年在澳大利亚开展的ADG106-1003联合疗法的Ib期数据 2021年下半年ADG106-2001的全球II期（探索生物标志物指导下的单一/联合实验）数据在美国和中国分别完成了ADG106-1001和ADG106-1002的临床试验患者招募。与FDA成功举行了I期临床结束会议。试验数据显示ADG106具备良好的安全性和耐受性，支持进一步的临床研究。 ADG106在剂量最高达到10...

Paleo Resources Announces Transaction With Field Genie, Inc.

Written by Customer Service on April 1, 2021. Posted in Public Companies.

CALGARY, Alberta, April 01, 2021 (GLOBE NEWSWIRE) — Paleo Resources, Inc. (“Paleo” or the “Corporation”) (TSX-V: PRE, OTCQB: PRIEF) announces that it has entered into a Common Stock Purchase and License Agreement with Field Genie, Inc. Field Genie, Inc. is a technology service provider that uses advanced artificial intelligence techniques to deliver solutions using spatial/geo intelligence and computer vision, including real-time detection and recognition of objects and patterns. Material terms of the agreement are as follows: (a) Field Genie, Inc. to provide Paleo (and its subsidiaries as directed by Paleo) technology development services during the 12 month term of the Agreement, with a focus on further development and build out of the digital investment platform of Energy Funders Resources, Paleo’s indirect wholly owned...

Cluny Capital Corp. Announces Voting Results of Its Annual and Special Meeting of Shareholders

Written by Customer Service on April 1, 2021. Posted in Public Companies.

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) — Cluny Capital Corp. (the “Company” or “Cluny”) (TSXV:CLN.H), a capital pool company pursuant to Policy 2.4 (“Policy 2.4”) of the TSX Venture Exchange (the “Exchange”), is pleased to announce the voting results of its annual and special meeting of shareholders held on March 31, 2021. In addition to the election of directors, the re-appointment of the auditors, and the re-approval of the Company’s stock option plan, shareholders approved certain matters which are conditional on completion of the Company’s business combination transaction with Teonan Biomedical Inc., including (i) the change the name of the Company to “The Good Shroom Co Inc.” (Les bons Champignons inc); (ii) the continuance of the Company from an Ontario corporation to a corporation under the Canada Business Corporations Act;...

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

Written by Customer Service on April 1, 2021. Posted in Public Companies.

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021. Jay Roberts, Chief Executive Officer of Vyant Bio, will discuss corporate, scientific, and operational updates in relation to the Company’s recent merger between the predecessor, Cancer Genetics, Inc., and StemoniX, Inc. Mr. Roberts will be joined on the call by Vyant Bio’s Chief Innovation Officer, Ping Yeh, and Chief Financial Officer, Andy LaFrence. Please also visit the Investors’...

Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

Written by Customer Service on April 1, 2021. Posted in Public Companies.

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science...

Aveanna Files Registration Statement for Proposed Initial Public Offering

Written by Customer Service on April 1, 2021. Posted in Public Companies.

ATLANTA, April 01, 2021 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Aveanna intends to list its common stock on the NASDAQ Global Select Market under the ticker symbol “AVAH.” The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed. Barclays, J.P. Morgan, BMO Capital Markets and Credit Suisse are acting as joint lead book-running managers, and BofA Securities, Deutsche Bank Securities, Jefferies, RBC Capital Markets and Truist Securities...

TC Energy to Redeem Cumulative Redeemable Minimum Rate Reset First Preferred Shares, Series 13

Written by Customer Service on April 1, 2021. Posted in Public Companies.

CALGARY, Alberta, April 01, 2021 (GLOBE NEWSWIRE) — News Release – As previously indicated, TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will redeem its issued and outstanding Cumulative Redeemable Minimum Rate Reset First Preferred Shares, Series 13 (Series 13 Shares) (TSX:TRP.PR.J) on May 31, 2021 (Redemption Date) at a price equal to $25.00 per share (Redemption Price) and provided notice today to the sole registered holder of the Series 13 Shares in accordance with their terms. Subject to board approval, the Company expects to declare a final quarterly dividend of $0.34375 per Series 13 Share, for the period up to but excluding May 31, 2021, payable on May 31, 2021 to shareholders of record on May 17, 2021. This would be the final dividend on the Series 13 Shares and, as the Redemption Date is also a dividend...

Canoe EIT Income Fund Announces April 2021 Distribution

Written by Customer Service on April 1, 2021. Posted in Public Companies.

CALGARY, Alberta, April 01, 2021 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the April 2021 distribution of $0.10 per unit. The distribution will be paid on May 14, 2021 to unitholders of record on April 22, 2021. The ex-distribution date for this distribution is April 21, 2021. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under the symbols EIT.UN, EIT.PR.A and EIT.PR.B, and is actively managed by Robert Taylor, Senior Vice President and Portfolio Manager, Canoe Financial. About Canoe FinancialCanoe Financial is one of Canada’s fastest growing independent mutual...

Day: April 1, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice